Preparation of 3,3'-(7-phenylpyrimido[4,5-d]pyrimidin-2,4-diyl)-di(8-oxa-3-azabicyclo[3.2.1]octane);3-[2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-phenylpyrimido[4,5-d]pyrimidin-4-yl]-8-oxa-3-azabicyclo[3.2.1]octane
CAS
——
化学式
C24H26N6O2
mdl
——
分子量
430.509
InChiKey
WMOMDLULDCLWSU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
3.2
重原子数:
32
可旋转键数:
3
环数:
7.0
sp3杂化的碳原子比例:
0.5
拓扑面积:
76.5
氢给体数:
0
氢受体数:
8
文献信息
Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof
申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
公开号:US20150368274A1
公开(公告)日:2015-12-24
The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction.
PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
申请人:Shanghai Institute of Materia Medica,
Chinese Academy of Sciences
公开号:EP2966079A1
公开(公告)日:2016-01-13
The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutical acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction.
[EN] PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRIDOPYRIMIDINE OU DE PYRIMIDOPYRIMIDINE, PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DE CELUI-CI